deb_jorn

Valeant company group chairman and executive vice president resigns

pharmafile | March 3, 2016 | Appointment | Medical Communications, Sales and Marketing Valeant, appointed, resignation 

In an already troubled week for Valeant Pharmaceuticals, the company has now announced that its group chairman and executive vice president, Deb Jorn, has resigned her position. She was responsible for the Canada-based firm’s major US dermatology and gastrointestinal therapeutic areas.

Estimated to represent half of Valeant’s forecasted 2016 US revenues, these two businesses are vital to the company’s performance. Its dermatology business, of course, is under severe scrutiny following the Philidor scandal.

A management shake-up has followed with Eric Abramson, vice president dermatology and immunology marketing, appointed general manager of the US dermatology business. Dr Ari Kellen, meanwhile, executive vice president and company group chairman will be in control of Valeant’s gastrointestinal business.

A statement from Valeant has indicated that it is their understanding that Jorn left the role for personal reasons and that her departure is “not the result of an action taken by the Ad Hoc Committee of the Board of Directors.”

Advertisement

Related Content

valeant_web

FDA rejects Valeant plaque psoriasis lotion over pharmacokinetic concerns

Beleaguered pharma firm Valeant has come up against another bump in the road as its …

top_ten

Top Ten most popular articles on Pharmafile.com this week

It’s been a week in which one of the largest pharmaceutical takeovers in history took …

valeant_web

Valeant seeks clean slate with rebrand, new company name

In the latest attempt to reverse its ailing fortunes and distance itself from its polluted …

The Gateway to Local Adoption Series

Latest content